New ADAP Advocacy Infographic Exposes Critical Failures in the 340B Drug Pricing Program

GTTP

340B drug purchases exceeded $100 billion in 2025 across 42,000 entities.
Charity care provided by hospitals continues to decline despite program growth.
The infographic exposes the correlation between rising executive compensation and patient medical debt.
ADAP Advocacy calls for greater transparency under its '340B Too Big To Fail' campaign.

Impact - Why it Matters

This infographic is significant because it provides a data-driven critique of the 340B program's accountability. By highlighting the gap between massive financial expansion and declining charity care, it pressures policymakers to address systemic inequities and ensures that federal drug pricing benefits truly reach the intended vulnerable patient populations.

Summary

ADAP Advocacy has released a compelling new infographic as part of its 340B Project, further examining the systemic issues within the 340B Drug Pricing Program. This visual resource builds upon the core themes of the organization’s previous policy paper, "340B PROGRAM: The Glue That Should Hold Our Healthcare System Together." While the program was originally designed by Congress to leverage federal resources for improved patient care, the data suggests it is increasingly falling short of its fundamental mission.

Despite 340B drug purchases surpassing $100 billion in 2025 across thousands of covered entities, the program's rapid growth has not translated into better outcomes for vulnerable populations. The infographic serves as a cornerstone of the '340B Too Big To Fail' campaign, providing a stark visual analysis of how hospital charity care continues to decline. It specifically highlights the disconnect between the program's massive financial scale and the rising medical debt faced by patients nationwide.

By connecting these trends, ADAP Advocacy aims to hold the healthcare industry accountable for its lack of transparency and declining social responsibility. The infographic sheds light on the concerning rise in executive compensation alongside decreasing charity services. Interested stakeholders and the public can download this critical resource online to better understand the urgent need for reform within the current healthcare landscape.

New ADAP Advocacy Infographic Exposes Critical Failures in the 340B Drug Pricing Program

GTTP

340B drug purchases exceeded $100 billion in 2025 across 42,000 entities.
Charity care provided by hospitals continues to decline despite program growth.
The infographic exposes the correlation between rising executive compensation and patient medical debt.
ADAP Advocacy calls for greater transparency under its '340B Too Big To Fail' campaign.